Support 100 years of independent journalism.

  1. Science & Tech
  2. Coronavirus
24 April 2020updated 06 Oct 2020 9:45am

Antiviral drug remdesivir fails first randomised clinical trial, according to WHO document

By Samuel Horti

Remdesivir, the antiviral drug that many hoped could treat Covid-19, has failed its first randomised clinical trial, according to draft documents accidentally published by the World Health Organization (WHO).

The drug had shown promise in early testing, but a Chinese trial showed that it did not improve patients’ condition or reduce the level of coronavirus in their bloodstreams.

According to the WHO document, scientists gave the drug to 158 people, and gave the remaining 79 a placebo. After a month, 13.9 per cent of patients taking the drug had died compared to 12.8 per cent of the placebo group. The trial was stopped early because of side-effects from the drug.

The company behind the drug, Gilead Sciences, said the document had mischaracterised the study. Trading of its shares was temporarily halted after investors dumped stock.

Select and enter your email address Quick and essential guide to domestic and global politics from the New Statesman's politics team. A weekly newsletter helping you fit together the pieces of the global economic slowdown. The New Statesman’s global affairs newsletter, every Monday and Friday. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s weekly environment email on the politics, business and culture of the climate and nature crises - in your inbox every Thursday. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A newsletter showcasing the finest writing from the ideas section and the NS archive, covering political ideas, philosophy, criticism and intellectual history - sent every Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
  • Administration / Office
  • Arts and Culture
  • Board Member
  • Business / Corporate Services
  • Client / Customer Services
  • Communications
  • Construction, Works, Engineering
  • Education, Curriculum and Teaching
  • Environment, Conservation and NRM
  • Facility / Grounds Management and Maintenance
  • Finance Management
  • Health - Medical and Nursing Management
  • HR, Training and Organisational Development
  • Information and Communications Technology
  • Information Services, Statistics, Records, Archives
  • Infrastructure Management - Transport, Utilities
  • Legal Officers and Practitioners
  • Librarians and Library Management
  • Management
  • Marketing
  • OH&S, Risk Management
  • Operations Management
  • Planning, Policy, Strategy
  • Printing, Design, Publishing, Web
  • Projects, Programs and Advisors
  • Property, Assets and Fleet Management
  • Public Relations and Media
  • Purchasing and Procurement
  • Quality Management
  • Science and Technical Research and Development
  • Security and Law Enforcement
  • Service Delivery
  • Sport and Recreation
  • Travel, Accommodation, Tourism
  • Wellbeing, Community / Social Services
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy
THANK YOU

Content from our partners
How industry is key for net zero
How to ensure net zero brings good growth and green jobs
Flooding is a major risk for our homes